接受包含洛匹那韦/利托那韦（克力芝）方案治疗的HIV感染患者的代谢评估

Metabolic evaluation of HIV-infected patients receiving a regimen containing lopinavir/ritonavir (Kaletra).

作者信息

Lafeuillade Alain, Hittinger Gilles, Philip Gisèle, Lambry Véronique, Jolly Patricia, Poggi Cécile

机构信息

Department of Infectious Diseases, Chalucet Hospital, Toulon, France.

出版信息

HIV Clin Trials. 2004 Nov-Dec;5(6):392-8. doi: 10.1310/Q0TG-0V50-9JML-638U.

DOI:10.1310/Q0TG-0V50-9JML-638U

PMID:15682352

Abstract

PURPOSE

We have analyzed retrospectively the evolution of metabolic parameters in a cohort of 159 HIV-infected patients taking a lopinavir/ritonavir-containing regimen during a mean period of 15 months.

METHOD

This study was completed by an additional evaluation after strict 12 hours fasting of total cholesterol (TC), HDL-c, LDL-c, triglycerides (TG), glucose, and insulin levels in a subset of 100 patients from the cohort.

RESULTS

TC and TG levels increased early after introduction of lopinavir/ritonavir, but remained subsequently stable. After a median of 15 months, TC was greater than normal laboratory range in 46% of cases and TG levels were greater than normal laboratory range in 52% of cases. However, in nearly 90% of these cases, elevations were less than or equal to grade 2. These increases were dependant on CDC stage and lipid levels at lopinavir/ritonavir initiation. No impact on glucose metabolism was found.

CONCLUSION

These results are particularly reassuring for the use of lopinavir/ritonavir in everyday practice.

摘要

目的

我们回顾性分析了159例接受含洛匹那韦/利托那韦方案治疗的HIV感染患者在平均15个月期间代谢参数的变化情况。

方法

本研究通过对该队列中100例患者在严格禁食12小时后进行总胆固醇（TC）、高密度脂蛋白胆固醇（HDL-c）、低密度脂蛋白胆固醇（LDL-c）、甘油三酯（TG）、血糖和胰岛素水平的额外评估得以完成。

结果

引入洛匹那韦/利托那韦后，TC和TG水平早期升高，但随后保持稳定。在中位数为15个月时，46%的病例TC高于正常实验室范围，52%的病例TG水平高于正常实验室范围。然而，在这些病例中，近90%的升高程度小于或等于2级。这些升高取决于疾病控制与预防中心（CDC）分期以及开始使用洛匹那韦/利托那韦时的血脂水平。未发现对糖代谢有影响。